Valeant to repay series F tranche B term loans via new note add-on

By Sarah Lizee

Olympia, Wash., Nov. 13 – Valeant Pharmaceuticals International, Inc. plans to repay a portion of its outstanding series F tranche B term loan facilities due 2022 using proceeds from a $750 million add-on to its 5½% senior secured notes due 2025, according to a press release.

The company will also use cash on hand to repay the term loans.

Valeant is a Laval, Quebec-based specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.